A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma

Summary

This is an open-label phase II, multicenter study. Eligible patients will receive CP-751,871 in monotherapy (20 mg/kg IV infusion on Day 1 of 3-week cycles). Tumor check-up will be performed every 6-8 weeks. Treatment will be continued until disease progression or unacceptable toxicities according to the patient or the investigator.

Timeline

Start

2009-01

Primary completion

2010-09

Completion

2010-09

Drugs

Indications